Michael Paul Agius, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adenosine Triphosphate | 4 | 2022 | 1989 | 0.580 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5665 | 0.460 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2014 | 1246 | 0.330 |
Why?
|
Protein Conformation | 2 | 2022 | 3969 | 0.210 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2022 | 140 | 0.200 |
Why?
|
Phosphotransferases | 1 | 2022 | 303 | 0.180 |
Why?
|
Prodrugs | 1 | 2023 | 261 | 0.180 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2021 | 431 | 0.160 |
Why?
|
Antineoplastic Agents | 1 | 2022 | 13637 | 0.160 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 180 | 0.150 |
Why?
|
Mucin-1 | 1 | 2020 | 540 | 0.130 |
Why?
|
Gadolinium | 1 | 2020 | 960 | 0.120 |
Why?
|
Papain | 1 | 2014 | 65 | 0.120 |
Why?
|
Point Mutation | 1 | 2019 | 1596 | 0.110 |
Why?
|
Receptors, Opioid, delta | 1 | 2013 | 48 | 0.110 |
Why?
|
Protein Kinases | 1 | 2020 | 1607 | 0.110 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5146 | 0.110 |
Why?
|
Models, Molecular | 2 | 2021 | 5439 | 0.100 |
Why?
|
Receptors, Opioid, mu | 1 | 2013 | 167 | 0.100 |
Why?
|
Immunoconjugates | 1 | 2020 | 954 | 0.100 |
Why?
|
Coronavirus | 1 | 2014 | 154 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1588 | 0.090 |
Why?
|
Peptide Hydrolases | 1 | 2014 | 621 | 0.090 |
Why?
|
Proteome | 1 | 2020 | 1862 | 0.090 |
Why?
|
Nanoparticles | 1 | 2020 | 1955 | 0.080 |
Why?
|
Molecular Conformation | 2 | 2022 | 545 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2022 | 5305 | 0.070 |
Why?
|
Piperidines | 1 | 2013 | 1656 | 0.060 |
Why?
|
Piperazines | 1 | 2013 | 2523 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2014 | 3057 | 0.050 |
Why?
|
Catalytic Domain | 1 | 2021 | 705 | 0.040 |
Why?
|
Databases, Protein | 1 | 2020 | 387 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2020 | 3874 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2020 | 13337 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1947 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1320 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3614 | 0.030 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2014 | 188 | 0.030 |
Why?
|
X-Ray Diffraction | 1 | 2014 | 421 | 0.030 |
Why?
|
Humans | 9 | 2023 | 761423 | 0.030 |
Why?
|
Indicators and Reagents | 1 | 2014 | 462 | 0.030 |
Why?
|
Vero Cells | 1 | 2014 | 482 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2020 | 0.020 |
Why?
|
Cricetulus | 1 | 2013 | 814 | 0.020 |
Why?
|
Protein Binding | 2 | 2014 | 9352 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6215 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1893 | 0.020 |
Why?
|
CHO Cells | 1 | 2013 | 1388 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2446 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 22164 | 0.020 |
Why?
|
Cricetinae | 1 | 2013 | 2425 | 0.020 |
Why?
|
Mutagenesis | 1 | 2014 | 1232 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2013 | 1334 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2014 | 3076 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3845 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15605 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2020 | 12796 | 0.020 |
Why?
|
Animals | 4 | 2020 | 168441 | 0.020 |
Why?
|
Cell Survival | 1 | 2014 | 5790 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 16979 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9179 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81509 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11740 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 30045 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 59207 | 0.010 |
Why?
|
Female | 2 | 2020 | 392581 | 0.010 |
Why?
|
Middle Aged | 1 | 2020 | 220826 | 0.000 |
Why?
|
Adult | 1 | 2020 | 221148 | 0.000 |
Why?
|
Male | 1 | 2020 | 360736 | 0.000 |
Why?
|